<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a nuclear membrane-associated transcription factor that governs the expression of various inflammatory genes </plain></SENT>
<SENT sid="1" pm="."><plain>PPAR-gamma <z:chebi fb="4" ids="48705">agonists</z:chebi> protect peripheral organs from ischemic injury </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated whether the PPAR-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> is neuroprotective against focal ischemic brain injury </plain></SENT>
<SENT sid="3" pm="."><plain>C57/B6 mice underwent 1.5-h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, and received either vehicle or <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> treatment of 0.75, 1.5, 3, 6 or 12 mg/kg (n = 9 per group) </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurological function, expression of pro-inflammatory proteins and neutrophil accumulation were assessed after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>At 48 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was significantly decreased with 3-12 mg/kg of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, with a time window of efficacy of 2 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> at the optimal dose (6 mg/kg) </plain></SENT>
<SENT sid="6" pm="."><plain>Neutrophil accumulation was significantly decreased in the brain parenchyma of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>-treated mice </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-induced expression of several inflammatory cytokines and chemokines was markedly reduced in <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>-treated brains, as determined using proteomic-array analysis </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> treatment improved neurological function at 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, in cultured cortical primary microglia, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> attenuated <z:mp ids='MP_0001845'>inflammatory responses</z:mp> by decreasing <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi>-induced release of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha, interleukin (IL)-1beta and IL-6 </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that the PPAR-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> has neuroprotective properties that are at least partially mediated via anti-inflammatory actions, and is thus a potential novel therapeutic agent for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>